

## **CONTENTS**

Preface ix

---

### **PART I PROPERTY AND PROGRESS**

1. Rising Expectations—and Diminishing Returns 3
  2. Property Generally: Externalities, Coordination, and the Public Domain 13
  3. Intellectual Property: The Public Domain and Private Rights 18
- 

### **PART II MAINTAINING THE PUBLIC/PRIVATE INTERFACE**

4. Taming Conflict of Interests 29
  5. Federally Sponsored Research Under Bayh-Dole 35
- 

### **PART III INTELLECTUAL PROPERTY AND ITS REGULATION**

6. The Anticommons 47
7. The Single Monopoly: Current Patent Limitations 54
8. Rate Regulation: An Unneeded Swamp 66

VIII CONTENTS

- 9. Patent Purchases: A Second Swamp 82
- 10. Socialization of R&D: The Final Swamp 97

---

**PART IV THE FDA: PURITY, SAFETY, EFFECTIVENESS**

- 11. The Steady Expansion of FDA Power 109
- 12. FDA Versus the Individual: Upstream or Downstream Decision Making 113
- 13. Drug Withdrawal: Too Much, Too Soon 132

---

**PART V PHARMACEUTICAL MARKETING**

- 14. Getting the Drugs to Market 143
- 15. Deceptive Marketing 165

---

**PART VI LIABILITY FOR PHARMACEUTICALS**

- 16. Tort Preliminaries 185
- 17. Product Liability for Prescription Drugs: Manufacturing and Design Cases 194
- 18. The Main Event: Misrepresentation, Overpromotion, and Duty to Warn 202

---

Conclusion: Socialized Medicines 237

Notes 241

Index 273